Aims To characterise the clinical features of human leucocyte antigen (HLA)-B27
AbsTrACT

InTroduCTIon
Acute anterior uveitis (AAU) is the most common uveitis entity worldwide and is characterised by inflammation of the anterior chamber lasting no longer than 3 months. The genetic marker human leucocyte antigen (HLA)-B27 is strongly associated with AAU, whereby the percentage of HLA-B27 positivity among AAU patients varies between 12% and 88%. [1] [2] [3] [4] It has been reported that AAU associated with HLA-B27 accounts for up to 81% of AAU cases in Taiwan, 5 a frequency that is much higher than that reported from many other countries. Earlier reports from our group in mainland China found that 63% of AAU patients were HLA-B27 + . 6 HLA-B27 + AAU is frequently associated with seronegative spondyloarthropathies, such as ankylosing spondylitis (AS), inflammatory bowel disease, psoriatic arthritis and reactive arthritis. 7 Although seronegative spondyloarthropathies share certain clinical characteristics, the pattern of ocular involvement is somewhat different for each entity. 8 AS is considered to be the major systemic disease presentation (55%-90%) 9 AAU was defined as the presence of inflammatory cells in the anterior chamber and dust-like keratic precipitates with aqueous flare, absence of posterior vitreous cells and other features of posterior segment inflammation apart from macular and optic disc oedema. The intraocular inflammation was characterised by a sudden onset with a duration of less than 3 months. 12 In this study, we only compared the differences of the clinical manifestation between HLA-B27 + AS + AAU patients and HLA-B27 + AS − AAU patients. Therefore, patients were excluded if (1) the HLA test or sacroiliac joint radiographs were not available, (2) Clinical science they had a follow-up less than 3 months, (3) they had a viral (herpes simplex virus (HSV)1, HSV2, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus) or bacterial (luetic or tubercular) aetiology, (4) the patients with other uveitis entities such as Behcet's disease or Vogt-Koyanagi-Harada syndrome or sarcoidosis and (5) the AAU was accompanied with other spondyloarthropathies such as inflammatory bowel disease, psoriatic arthritis, reactive arthritis and sarcoidosis since the numbers of such cases was quite small. AS was diagnosed by rheumatologists according to the Modified New York Criteria. 13 The radiological examinations of the sacroiliac joint included radiographs, CT or MRI and were evaluated by specialists from our rheumatology or orthopaedics department.
The onset of uveitis, laterality, the age at first attack, disease course since first episode of AAU, as well as inflammatory back pain or morning stiffness, release position and other general history parameters were recorded. A complete ophthalmic evaluation including best corrected visual acuity (BCVA), slit-lamp examination of the anterior and posterior segment, intraocular pressure (IOP) and fundus examination after pupillary dilation was performed. Fundus fluorescence angiography (FFA) was non-selectively performed. FFA was also confirmed by clinical manifestation and optical coherence tomography (OCT) findings. FFA was not performed in case of opacity in the ocular refractive pathway, renal or cardiac disease or hypersensitivity to fluorescein. Blood testing (complete blood count, HLA-B27 test) were routinely included. Rheumatological examination, chest and sacroiliac radiographs, CT or MRI were obtained for each patient. Disease activity of AS was also evaluated using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (range 0-10), 14 and Bath Ankylosing Spondylitis Functional Index (BASFI) (range 0-10). 15 AAU was treated with topical steroids combined with cycloplegic eye-drops. In a few patients with massive fibrous exudates in the anterior chamber or hypopyon, oral corticosteroids (usually 20 mg prednisone per day as initial dose) were also used for 3 to 4 weeks. Subconjunctival injection of triamcinolone was performed in patients with contraindications such as increased blood glucose level, severe gastroduodenal ulcer or osteoporosis. The patients with AS were also treated with systemic low-dose corticosteroids (usually 20 mg/day) combined with ciclosporin (generally 3 mg/kg/day) or recommended to be treated by specialists from our rheumatology or orthopaedics department.
statistical analysis
Data analysis was performed using SPSS V. 16 figure 1) . Cystoid macular oedema (1.7%) and optic disc hyperfluorescence (5.4%) were also found in the affected eyes of certain patients. There was no correlation between retinal vascular leakage and gender, onset age, clinical features including fibrinous exudation, corneal endothelium wrinkling, hypopyon and synechiae, complications including complicated cataract, transiently increased IOP, secondary glaucoma, neovascularisation of the iris and hypotony, nor was there any correlation between the FFA findings and IOP, as well as visual acuity.
Complications and visual outcome
Complications including complicated cataract, transiently increased IOP, secondary glaucoma, neovascularisation of the iris and hypotony were recorded at each visit during follow-up. The most common complication was complicated cataract (16.3%), followed by transiently increased IOP secondary to active inflammation in the anterior chamber (7.6%) and secondary glaucoma (4.3%).
The percentage of complicated cataract and secondary glaucoma was significantly higher in the HLA-B27 + AS + group as compared with the HLA-B27 + AS − group (table 4) . No significant difference was found in the percentage of other complications between the two groups of patients. Visual improvement was observed in patients following treatment except those who had a complete opacity of the lens, severe optic nerve atrophy or hypotony. BCVA was monocularly assessed and recorded in LogMAR scores by using the standard logarithmic visual acuity chart. Worse visual outcome as shown by a higher percentage of patients with a BCVA <0.5 or a BCVA <0.05 was noted in the HLA-B27 + AS + group as compared with the HLA-B27 + AS − group, both before and after treatment (table 5) . The BCVA at the last visit was negatively correlated with onset age (r=−0.334, p<0.001) and the presence of cataract (r=−0.416, p<0.001).
dIsCussIon
Our uveitis clinic is the largest tertiary uveitis centre in China, and to our knowledge, this study represents the largest retrospective epidemiological survey of HLA-B27 + AAU in mainland China. Among the patients with AAU being referred to our clinic during the last 8 years, it appeared that HLA-B27 + AAU was the most common entity with a percentage of 61.5% among all AAU patients. Since we focused on the question how the occurrence of AS affects the manifestations of HLA-B27 + AAU, the HLA-B27 + AAU patients with other seronegative spondyloarthropathies such as inflammatory bowel disease, psoriatic arthritis, reactive arthritis and sarcoidosis were excluded from this study. The result revealed that HLA-B27 + AS + AAU patients showed 
AS
+ AAU patients is in agreement with earlier studies. 16 17 A larger degree of bilateral/alternating involvement in HLA-B27 + AS + AAU patients, is also consistent with earlier studies. 18 A more intense inflammatory reaction as evidenced by the appearance of fibrinous exudates in the anterior chamber in HLA-B27 + AS + AAU patients as compared with the HLA-B27 + AS − AAU patients as found in our study, has also been noted earlier by others. 19 It has been documented that AAU may affect the posterior segment, although there are no apparent retinal or choroidoretinal lesions. 20 OCT analysis has shown that eyes with acute anterior uveitis had thickened maculae and peripapillary retinal nerve fibre layer as compared with controls. 21 Macular thickness was closely correlated with the inflammation in anterior uveitis patients with spondyloarthropathy. 22 Shulman et al 21 assumed that this might be associated with a breakdown in the blood-aqueous and blood-retinal barriers and an increase in vascular permeability. These earlier investigations all focused on the posterior pole but did not assess the peripheral retina. FFA has been widely used to evaluate abnormalities of the retina, retinal blood vessels and optic nerve. Using this technique, it was interesting to note that a number of abnormalities including retinal vascular leakage, cystoid macular oedema and optic disc hyperfluorescence were observed in HLA-B27 + AAU patients, and as mentioned above, retinal vascular fluorescence leakage was not uncommon in these patients. It is not clear whether this abnormality is caused by a direct retinal involvement of the inflammation or whether it is caused by an effect of inflammatory mediators released from the anterior segment. Fortunately, the abnormalities including retinal vascular leakage, cystoid macular oedema and optic disc hyperfluorescence disclosed by FFA were not correlated to visual outcome, and resolved immediately following the disappearance of anterior segment inflammation without any complications. FFA is therefore not crucial in guiding the ophthalmologist concerning the further management of these patients and merely indicates posterior segment involvement. Of interest is the observation that endotoxin-induced uveitis, which serves as an experimental animal model of AAU, is also associated with posterior segment involvement as evidenced by retinal macrophage infiltration. 23 It has been reported that AS or the association with HLA-B27 may influence the occurrence of complications and visual prognosis in AAU. 19 24 25 Complications including complicated cataract, ocular hypertension, secondary glaucoma and cystoid macular oedema were less common in HLA-B27 + AAU patients as compared with HLA-B27 − AAU patients. 19 25 However, no significant difference in complications or visual outcome were reported between HLA-B27 + AAU patients with or without AS. 26 In general, the HLA-B27 + patients had a better visual prognosis as compared with uveitis patients with Vogt-Koyanagi-Harada syndrome 27 or Behcet's disease. 28 A poorer visual outcome was found in patients with AS, which is probably due to the higher frequency of complicated cataract.
There are several limitations in our study. It is a retrospective study and some of the results, such as the observation of the high degree of retinal vascular leakage, should be confirmed in prospective studies. Although the FFA findings have not yet changed our management of these patients, further study is needed to investigate the prognosis of patients with serious retinal vascular leakage and whether they would benefit from earlier and more aggressive treatment. In the 581 AS patients with AAU, only 42 patients were treated by specialists in rheumatology or orthopaedics with tumour necrosis factor (TNF) inhibitors. As the durations and dosages of the treatment were different, it is not clear whether the TNF inhibitors could influence the visual prognosis and FFA findings in these patients. It is also not clear whether these retinal findings are a typical manifestation in Chinese patients and comparison with patients from other ethnic backgrounds is needed to clarify this issue. A variety of treatment regimens including corticosteroids, non-steroidal anti-inflammatory drugs, immunosuppressive agents and biological agents have been used for the treatment of our AS patients and comparison with patients without AS who received a milder treatment may therefore be a controversial issue. Despite the more aggressive treatment, the AS patients did worse and we would like to conclude that the occurrence of AS in our AAU patients is a manifestation of a more serious form of the same disease, although further studies are needed to support this hypothesis.
In conclusion, our study characterised the clinical features of HLA-B27 + AAU with or without AS based on a large cohort of Chinese patients. Interestingly, our study showed that retinal vascular involvement was a relatively common manifestation in these patients. Our results also demonstrated a male predominance, bilateral/alternating involvement and poorer visual prognosis in HLA-B27 + AAU patients with AS. 
